Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | Overview of the SIRIUS clinical trial in the treatment of multiple myeloma

Maria-Victoria Mateos, MD, PhD from the University Hospital of Salamaca, Spain provides an overview of the SIRIUS clinical trial of daratumumab, an anti-CD38 monoclonal antibody, in the treatment of relapsed/refractory multiple myeloma (MM) patients. Approximately 100 patients received daratumumab as a single-agent, and 30% of these responded to daratumumab. Dr Mateos discusses the importance of these results, as currently treatment for this patient population is an unmet need.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.